Utrecht, The Netherlands, July 12, 2015 – Crossbeta Biosciences today announced that it has completed a round of internal financing. In addition, the company secured another Innovation Grant from the Dutch government agency RVO for the further development of Crossbeta’s platform technology and stable oligomers in the field of Alzheimer’s, Parkinson’s, ALS and Huntington’s disease.
“We are very pleased by this recognition of the potential of our unique technology. It confirms the value the resulting Crossbeta assets bring to the neurology research and development community,” said Guus Scheefhals, CEO of Crossbeta Biosciences. “This financial contribution signifies the continued commitment of our shareholders and allows us to expand the portfolio of disease-relevant oligomers. We are looking forward to contribute, in a highly unique and relevant way, to an even broader range of therapeutic and diagnostic programs of our strategic partners, fighting devastating neurologic disorders.”